Also found in: Dictionary.


Cardiology A tablet containing irbesartan/Avapro®, an angiotensin II receptor blocker, and hydrochlorothiazide, a thiazide diuretic for hypertensive Pts whose BP is poorly controlled by either agent as a monotherapy See Hypertension.
Mentioned in ?
References in periodicals archive ?
Bristol-Myers Squibb reported worldwide sales of Avalide and Avapro of $307 million for the first half of 2010, which was down 2% from the 2009 period.
The product, marketed as Avalide by Bristol-Myers Squibb (BMS), was approved in 1997 for treating hypertension, with a statement in its label that says the combination therapy should not be used until a patient has failed to achieve the desired effect with monotherapy.
The first, a pivotal trial of 695 patients (mean age 52 years) with severe hypertension (an untreated diastolic blood pressure of at least 110 mm Hg or on monotherapy with a diastolic blood pressure of at least 100 mm Hg), compared Avalide with irbesartan monotherapy as initial therapy.
In the pivotal trial, 47% of patients on Avalide had achieved a diastolic blood pressure below 90 mm Hg at 5 weeks, the primary end point, compared with 33% of patients on irbesartan monotherapy, which was a highly significant difference.
Among the 92 patients 65 and older, Avalide was well tolerated, there were no cases of hypotension or syncope, and dizziness was not more common than in younger patients.
Pharmaceutical company Mylan Inc (NasdaqGS:MYL) reported on Friday the receipt of final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Irbesartan Tablets USP, 75mg, 150mg and 300mg, the generic version of Sanofi's Avalide.
M2 PHARMA-April 2, 2012-Teva launches generic Avapro and generic Avalide in the US(C)2012 M2 COMMUNICATIONS
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) on Monday announced that it has begun the commercial launch of Irbesartan and Irbesartan-Hydocholothiaxide tablets, the company's generic versions of Sanofi Aventis' high blood pressure treatments Avapro and Avalide tablets.
Next year, Maciw noted, an even larger number of key products, including Nexium, Diovan/ HCT, Avapro, Atacand, Singulair, Avalide, Nasonex, Avandia, Reminyl ER, Taxatore, Strattera, and Zomig/R will all come off patent, representing some $2.
patent expirations for Avapro/ Avalide (down 56% to $95 million) and Plavix (down 96% to $64 million).